Larimar Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Larimar Therapeutics, Inc. on May 10, 2022. The report details corporate governance events, specifically executive compensation awards and the results of the 2022 Annual Meeting of Stockholders held virtually on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate actions rather than financial performance metrics.
Material Changes and Corporate Actions
- Executive Compensation: On May 10, 2022, the Company granted retention stock options under the 2020 Equity Incentive Plan to key executives:
- Carole Ben-Maimon, M.D. (CEO): 40,000 options.
- Michael Celano (CFO): 20,000 options.
- Vesting Schedule: Options vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments.
- Shareholder Voting: As of the April 4, 2022 record date, there were 17,710,450 outstanding shares entitled to vote.
Annual Meeting Results
Stockholders approved all three proposals submitted at the Annual Meeting:
- Election of Class II Director: Thomas E. Hamilton was elected to serve until the 2025 Annual Meeting.
- For: 10,706,016
- Withheld: 4,054,348
- Broker Non-Votes: 1,129,162
- Advisory Vote on Executive Compensation (Say-on-Pay): Stockholders approved the 2021 compensation of named executive officers.
- For: 13,936,241
- Against: 49,830
- Abstentions: 774,980
- Broker Non-Votes: 1,129,162
- Ratification of Independent Auditor: PricewaterhouseCoopers LLP was ratified for the 2022 fiscal year.
- For: 15,888,293
- Against: 1,558
- Abstentions: 362
- Broker Non-Votes: 0
Outlook, Risks, and Contingencies
The filing text does not provide specific guidance, outlook, management commentary on future operations, or new risk factors. The document is limited to reporting the execution of equity awards and the outcome of shareholder votes.
Key Facts for Investor Verification
- Verify the total number of outstanding shares and the impact of the new option grants on potential dilution.
- Review the definitive proxy statement filed on April 12, 2022, for detailed biographical information on the newly elected director, Thomas E. Hamilton.
- Confirm the vesting conditions and exercise price of the options granted to the CEO and CFO in the Company's 2020 Equity Incentive Plan.
- Note the significant number of broker non-votes (1,129,162) on the director election, indicating shares held by brokers that were not voted due to lack of instructions.